Идёт набор NCT07037459

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Фаза III С лечением Heart Failure With Preserved Ejection Fraction Heart Failure With Mildly Reduced Ejection Fraction Obesity

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: Maridebart cafraglutide, Placebo.
Кому может быть актуально: Состояния в реестре: Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity. Базовые параметры: 18 лет — 99 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США, Аргентина, Австралия, Австрия, Бельгия +29
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

Обзор

This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

Вмешательства

Препарат Maridebart cafraglutide
Maridebart cafraglutide will be administered SC.
Препарат Placebo
Placebo will be administered SC.

Первичные конечные точки

Time to First Occurrence of a Composite Endpoint Consisting of: CV Death or HF Events [Срок оценки: Up to approximately 35 months]

Вторичные конечные точки (12)

Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) for Participants with Baseline KCCQ-CSS Score ≤ 80 [Срок оценки: Baseline and Week 48]
Change from Baseline in the KCCQ Total Symptom Score (TSS) for Participants with Baseline KCCQ-CSS Score ≤ 80 [Срок оценки: Baseline and Week 48]
Total Number of HF Events Including First and Recurrent HF Events [Срок оценки: Up to approximately 35 months]
Time to First Occurrence of a Composite Endpoint Consisting of: Myocardial Infarction (MI), Ischemic Stroke, CV Death (Major Adverse Cardiac Events [MACE]), or HF Events [Срок оценки: Up to approximately 35 months]
Time to First Event of a Composite Nephropathy Endpoint [Срок оценки: Up to approximately 35 months]
Change in eGFR Slope (Total) [Срок оценки: Baseline up to approximately 35 months]
Change in eGFR Slope (Chronic) [Срок оценки: From 4 months up to approximately 35 months]
Time to Onset of Type 2 Diabetes Mellitus (T2DM) in Participants with Prediabetes [Срок оценки: Up to approximately 35 months]
Time to the First HF Event [Срок оценки: Up to approximately 35 months]
Change from Baseline in the Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) [Срок оценки: Baseline and Week 72]
Change from Baseline in Body Mass Index (BMI) (kg/m^2) [Срок оценки: Baseline and Week 72]
Change from Baseline in the Waist Circumference (cm) [Срок оценки: Baseline and Week 72]

Критерии участия

Критерии включения

Age ≥ 18 years at the time of informed consent.
BMI ≥ 30.0 kg/m\^2 at randomization.
HF diagnosed for at least 30 days with New York Heart Association (NYHA) Class II-IV at the time of informed consent.
Managed with HF standard of care therapies.
Left ventricular ejection fraction (LVEF) of > 40% within 12 months before randomization.

Критерии исключения

History of any of the following within 60 days prior to or during screening: Type I (spontaneous) MI, valvular replacement or repair, coronary revascularization, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke.
HF due to: hypertrophic cardiomyopathy, infiltrative cardiomyopathy, active or chronic myocarditis, constrictive pericarditis, cardiac tamponade, arrhythmogenic right ventricular or left ventricular cardiomyopathy/dysplasia, uncorrected primary valvular heart disease, clinically significant congenital heart disease.
Hospitalized with acute decompensated HF at the time of or during the screening period.
Type 1 diabetes mellitus, or any type of diabetes with the exception of T2DM or history of gestational diabetes.
For participants with a prior diagnosis of T2DM (including those diagnosed during screening):

HbA1c > 10.0% (86 mmol/mol) at screening
Uncontrolled diabetes requiring immediate therapy
History of diabetic ketoacidosis or hyperosmolar state/coma within 12 months before randomization
One or more episodes of severe hypoglycemia within 6 months before randomization and/or history of hypoglycemia unawareness
History or presence of either proliferative diabetic retinopathy, or diabetic maculopathy, or severe non-proliferative diabetic retinopathy; or currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.
SBP ≥ 180 mmHg during the screening period, or on three or more blood pressure-lowering drugs with a SBP > 160 mmHg during the screening period (including day 1 prior to randomization).
History of chronic pancreatitis or acute pancreatitis in the 180 days before screening or during the screening period.
Any personal lifetime history of, or family history(first-degree relative\[s\]) of medullary thyroid carcinoma or MEN-2.
eGFR < 20 mL/min/1.73 m\^2 (CKD-EPI creatinine (Cr)-cystatin C equation) or receiving dialysis at screening.
Calcitonin ≥ 50 ng/L (pg/mL) at screening.
Acute or chronic hepatitis.
Any of the following psychiatric history:

History of unstable major depressive disorder or other severe psychiatric disorder within 2 years prior to screening or during the screening period
Lifetime history of suicide attempt
History of non-suicidal self-injury within 5 years prior to screening or during the screening period.
History of any other condition that, in the opinion of the investigator, may preclude the participant from following the protocol and completing the trial.
Use of any glucagon-like peptide 1 receptor agonist (GLP-1 RA), glucose-dependent insulinotropic polypeptide (GIP) agonists or antagonists, or amylin analogs within 90 days prior to or during the screening period or planned use during the conduct of the trial.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение: Рандомизированное
Модель: Параллельные группы
Маскирование: Двойное слепое
Основная цель: Лечение